Loading company…
Sino-Cell Biomed develops immune cell therapies for tumors and degenerative diseases.
Founded in 2019 in Qingdao, China, Sino-Cell Biomed researches and develops immune cell drugs for tumors and degenerative diseases. Its products include tumor-infiltrating lymphocyte drugs HS-IT101, HS-IT201, and HS-IT301, supported by its PowerTexp and TMExpT platforms. The company cooperates with Qingdao University and other organizations. In December 2023, it closed a Series A round to fund clinical trials for HS-IT101 and drug research license applications for HS-IT201 and IT301.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in